Biomaterial Database

The interactions of therapeutic antibodies with Fc receptors. 2012

Marcello Albanesi, and Marc Daëron

Institut Pasteur, Département d’Immunologie, Unité d’Allergologie Moléculaire & Cellulaire, Paris, France.

During the last two decades, a rapidly increasing number of therapeutic antibodies have been generated and used in a variety of diseases. The rationale of passive immunotherapy is that, due to their unique specificity, antibodies can selectively target and act on molecules associated with pathological processes. However, how therapeutic antibodies actually act on target molecules and cells under specific conditions is poorly known. As a consequence, whether the efficacy of available antibodies could be increased and whether new antibodies could be tailored for specific purposes have not been thoroughly investigated. We discuss in this review how therapeutic antibodies interact with Fc receptors, what are the cellular responses induced by these interactions and how a better knowledge of these interactions and biological responses could improve antibody-based passive immunotherapy.

UI	MeSH Term	Description	Entries
D011961	Receptors, Fc	Molecules found on the surface of some, but not all, B-lymphocytes, T-lymphocytes, and macrophages, which recognize and combine with the Fc (crystallizable) portion of immunoglobulin molecules.	Fc Receptors,Fc Receptor,Receptor, Fc
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818	Animals	Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA.	Animal,Metazoa,Animalia
D000906	Antibodies	Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).
D000918	Antibody Specificity	The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site.	Antibody Specificities,Specificities, Antibody,Specificity, Antibody
D000951	Antigens, Neoplasm	Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.	Neoplasm Antigens,Tumor Antigen,Tumor Antigens,Antigen, Tumor,Antigens, Tumor
D059016	Tumor Microenvironment	The milieu surrounding neoplasms consisting of cells, vessels, soluble factors, and molecules, that can influence and be influenced by, the neoplasm's growth.	Cancer Microenvironment,Cancer Microenvironments,Microenvironment, Cancer,Microenvironment, Tumor,Microenvironments, Cancer,Microenvironments, Tumor,Tumor Microenvironments
D017951	Antigen Presentation	The process by which antigen is presented to lymphocytes in a form they can recognize. This is performed by antigen presenting cells (APCs). Some antigens require processing before they can be recognized. Antigen processing consists of ingestion and partial digestion of the antigen by the APC, followed by presentation of fragments on the cell surface. (From Rosen et al., Dictionary of Immunology, 1989)	Antigen Processing,Antigen Presentations,Antigen Processings